…
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
AnaptysBio is a clinical-stage biotechnology company that develops therapeutic antibody product candidates using its proprietary antibody discovery platform, with programs focused on immunology, inflammatory diseases and oncology. Long-term growth may be driven by clinical trial progress, licensing or collaboration agreements and successful development or commercialization of lead candidates. Investors may find the company attractive for exposure to platform-based biologic innovation and potential upside if programs achieve regulatory approval.
Key risks include clinical and regulatory failure, ongoing financing needs given limited or no product revenue, and intense competition in antibody therapeutics.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -13.07M | -145.23M | -163.62M | -128.70M | -57.80M |
| Net income | -13.23M | -145.23M | -163.62M | -128.72M | -57.19M |
| Selling general administrative | 50.74M | 42.39M | 41.95M | 36.64M | 21.49M |
| Gross profit | 232.18M | -72.56M | -115.13M | 10.29M | 63.17M |
| Reconciled depreciation | 2.42M | 2.40M | 2.38M | 2.33M | 2.09M |
| Ebit | 47.90M | -95.14M | -157.07M | -115.15M | -56.81M |
| Ebitda | 50.32M | -92.74M | -156.42M | -107.59M | -56.35M |
| Depreciation and amortization | 2.42M | 2.40M | 0.65M | 7.56M | 0.47M |
| Non operating income net other | - | - | - | -18.37M | -1.40M |
| Operating income | 47.90M | -114.95M | -164.41M | -115.15M | -56.81M |
| Other operating expenses | 186.71M | 206.23M | 181.57M | 125.44M | 119.99M |
| Interest expense | 79.89M | 50.09M | 18.08M | 21.11M | 1.45M |
| Tax provision | 0.16M | 0.00M | -0.00M | 0.02M | 0.00M |
| Interest income | 13.50M | 19.79M | 17.83M | 7.55M | 0.43M |
| Net interest income | -66.39M | -30.29M | 0.46M | -13.56M | -1.02M |
| Income tax expense | 0.16M | 0.00M | -0.00M | 0.02M | -0.60M |
| Total revenue | 234.60M | 91.28M | 17.16M | 10.29M | 63.17M |
| Total operating expenses | 184.28M | 42.39M | 49.28M | 125.44M | 119.99M |
| Cost of revenue | 2.42M | 163.84M | 132.28M | - | - |
| Total other income expense net | -60.96M | -30.28M | 0.79M | -13.55M | -0.98M |
| Net income from continuing ops | -13.23M | -145.23M | -147.82M | -128.72M | -57.80M |
| Net income applicable to common shares | - | - | - | -128.72M | -57.80M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 364.39M | 483.83M | 452.39M | 610.38M | 643.07M |
| Other current assets | 4.76M | 5.74M | 9.08M | 4.54M | 4.90M |
| Total liab | 327.19M | 412.97M | 364.29M | 348.28M | 286.64M |
| Total stockholder equity | 37.21M | 70.87M | 88.10M | 262.10M | 356.43M |
| Other current liab | 32.67M | 39.50M | 30.97M | 21.63M | 12.85M |
| Common stock | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M |
| Capital stock | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M |
| Retained earnings | -772.56M | -759.33M | -614.10M | -450.48M | -321.75M |
| Other liab | - | - | - | 304.41M | 251.09M |
| Other assets | - | - | - | 0.26M | 0.26M |
| Cash | 238.20M | 123.08M | 35.97M | 71.31M | 495.73M |
| Total current liabilities | 38.62M | 45.43M | 37.44M | 26.05M | 16.10M |
| Net debt | -224.08M | 246.38M | -18.15M | -51.86M | -474.77M |
| Short term debt | 2.08M | 1.93M | 1.78M | 1.64M | 1.50M |
| Short long term debt total | 14.11M | 369.46M | 17.81M | 19.45M | 20.95M |
| Other stockholder equity | 809.76M | 829.86M | 702.97M | 717.80M | 678.58M |
| Property plant equipment | - | - | - | 2.09M | 2.28M |
| Total current assets | 350.25M | 431.88M | 406.83M | 447.20M | 553.88M |
| Long term investments | 0.00M | 35.47M | 27.03M | 142.94M | 67.10M |
| Net tangible assets | - | - | - | 584.33M | 626.97M |
| Short term investments | 73.44M | 262.29M | 354.94M | 369.93M | 52.37M |
| Net receivables | 33.85M | 40.77M | 6.85M | 1.42M | 0.88M |
| Inventory | - | - | 0.00M | - | -0.88M |
| Accounts payable | 3.87M | 4.00M | 4.70M | 2.78M | 1.74M |
| Accumulated other comprehensive income | -0.02M | 0.30M | -0.80M | -5.25M | -0.42M |
| Common stock total equity | - | - | - | 0.03M | 0.03M |
| Retained earnings total equity | - | - | - | -450.48M | -321.75M |
| Non currrent assets other | 0.26M | 0.26M | 0.26M | 0.26M | 0.26M |
| Non current assets total | 14.14M | 51.96M | 45.55M | 163.18M | 89.19M |
| Capital lease obligations | 14.11M | 16.04M | 17.81M | 19.45M | 20.95M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 228.12M | 95.40M | 117.07M | -394.49M | 40.19M |
| Change to liabilities | - | - | - | 9.70M | -4.74M |
| Total cashflows from investing activities | 228.03M | 95.40M | 144.75M | -394.85M | 38.84M |
| Total cash from financing activities | -132.61M | 127.05M | -59.30M | 44.02M | 252.30M |
| Change to operating activities | - | - | - | -2.32M | -1.87M |
| Net income | 49.61M | -145.23M | -163.62M | -128.72M | -57.80M |
| Change in cash | 115.12M | 87.11M | -35.34M | -424.42M | 245.21M |
| Begin period cash flow | 123.08M | 35.97M | 71.31M | 495.73M | 250.52M |
| End period cash flow | 238.20M | 123.08M | 35.97M | 71.31M | 495.73M |
| Total cash from operating activities | 19.70M | -135.34M | -120.80M | -73.59M | -45.92M |
| Issuance of capital stock | 14.26M | 100.84M | 5.63M | 11.83M | 2.55M |
| Depreciation | 2.42M | 2.40M | 2.38M | 2.33M | 2.09M |
| Other cashflows from investing activities | - | - | - | - | 0.01M |
| Dividends paid | - | - | 11.73M | - | - |
| Change to inventory | - | - | 5.11M | - | - |
| Change to account receivables | 6.92M | -33.91M | -5.43M | -0.54M | -0.88M |
| Sale purchase of stock | -68.63M | -0.46M | -50.00M | 11.83M | 2.55M |
| Other cashflows from financing activities | -1.45M | -8.10M | -0.04M | 32.19M | 249.75M |
| Change to netincome | - | - | - | 18.60M | 1.94M |
| Capital expenditures | 0.09M | 0.36M | 0.81M | 0.36M | 1.37M |
| Cash flows other operating | - | - | - | 26.16M | 14.05M |
| Cash and cash equivalents changes | - | - | - | -424.42M | 245.21M |
| Change in working capital | -80.72M | -66.33M | -0.32M | 6.84M | -7.49M |
| Stock based compensation | 36.07M | 34.05M | 33.20M | 27.36M | 15.35M |
| Other non cash items | 12.31M | 39.77M | 7.56M | 18.60M | 1.45M |
| Free cash flow | 19.61M | -135.69M | -121.61M | -73.95M | -47.29M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio Inc |
-1.52 3.18% |
46.25 | - | - | 9.02 | 52.15 | 7.00 | 23.73 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
10770 Wateridge Circle, San Diego, CA, United States, 92121-5801
858 362 6295
104
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel R. Faga | Interim Pres & CEO and Director | 1980 |
| Mr. Eric J. Loumeau | COO & Gen. Counsel | 1963 |
| Mr. Hamza Suria M.B.A., M.Sc. | Advisory | 1976 |
| Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D. | Chief Medical Officer | 1975 |
| Mr. Dennis M. Mulroy | Chief Financial Officer | 1955 |
| Mr. Benjamin Stone | Sr. VP of Corp. Devel. | NA |
| Ms. Beth Mueller | Sr. VP of HR | NA |
| Dr. Martin Dahl Ph.D. | Sr. VP of Research | NA |
| Mr. Daniel R. Faga | President, CEO & Director | 1980 |
| Mr. Eric J. Loumeau | Chief Legal Officer | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.